Short Interest & Thesis

Short Interest and Thesis — Molina Healthcare (MOH)

Reported short-interest, short-sale-volume, borrow, and peer-context data were all unavailable for this run, so positioning, crowding, and squeeze risk cannot be quantified here. The decision-useful short thesis instead comes from the primary record: a filed securities class action and a derivative suit alleging Molina failed to disclose deterioration in its medical cost trend assumptions during 1H 2025, set against a documented 2025 guidance arc that was cut from at-least-$24.50 of adjusted EPS to a $19 floor and then to roughly $14, with the Marketplace MCR rising from 75.4% to 90.6% year-on-year. The contested issues — Medicaid rate-versus-trend imbalance and Marketplace pricing volatility — were both standing risk-factor disclosures, so the unresolved question is one of timing and quantification of internal information, not whether the issues themselves were unknown.

Evidence Quality. Official reported short interest, FINRA short-sale volume, public net-short disclosures, borrow indicators, and peer short-interest context are all empty in this run's structured data. Conclusions below are confined to: (i) the disclosed short-thesis substance in the FY2025 10-K and 2025 transcripts, and (ii) liquidity/capital-structure context drawn from the same filings.

Reported short-interest data — unavailable

No Results

Source class summary drawn from the run's data/short_interest/manifest.json and latest.json — not from a corpus PDF. No reported-short-interest conclusion can be drawn from this run's data; do not substitute short-sale volume or anecdote for the missing position-level series.

Liquidity and float context (for a future positioning read)

Float and capital-structure context are sourced from the FY2025 10-K so the reader can size the implication if reported short interest becomes available later. Approximately 51.5 million shares of common stock were outstanding as of February 6, 2026 [1], and the board's April 2025 buyback authorization had $500 million remaining as of February 10, 2026, scheduled to run through year-end 2026 [2]. Share count has compressed materially over five years — from roughly 58.6M at FY2021 to 52.9M at FY2025 — indicating an active buyback program that shrinks the absorbable float for any short cover.

Figures in the chart are calendar-year period-end share counts from the staged income-statement data; the FY2025 February-6 share count cited above is the more current authoritative snapshot.

The disclosed public short thesis

There is one public, source-anchored short thesis to engage with. On October 3, 2025 a putative securities class action — Hindlemann v. Molina Healthcare, Inc., et al. — was filed in the U.S. District Court for the Central District of California against Molina, its CEO and its CFO, on behalf of holders who acquired the stock between February 5, 2025 and July 23, 2025, alleging violations of federal securities laws related to the Company's disclosures, including those involving earnings guidance [3]. A shareholder derivative action — Taylor v. Wolf, et al. — followed on December 12, 2025 against the directors and certain officers, asserting breach of fiduciary duty and securities-law violations in connection with the same statements and events; Molina states it intends to vigorously contest each lawsuit and that it cannot predict an outcome or reasonable estimate of loss [3].

The substantive allegation tracks the sequence of guidance revisions and MCR moves visible in management's own disclosures. The class period opens at the February 5, 2025 release in which Molina guided to adjusted EPS of at least $24.50, "8% growth over the full year 2024" (initial guide referenced in the plaintiff complaint summarized in the staged research). At the Q2 FY2025 print on July 23, 2025 the adjusted EPS floor was cut by $5.50 to "no less than $19," with management citing a "very challenging medical cost trend environment for each of our segments" [4]. At the Q3 FY2025 print on October 23, 2025 the guide was cut again, by a further ~$5 to approximately $14, with management acknowledging that "half of this revision emerges from the unprecedented utilization trend in Marketplace, which represents nearly 10% of our business" and "only one-third emerges from the rate and trend imbalance in Medicaid, which is 75% of our business" [5]. FY2025 then printed a consolidated MCR of 91.7% versus 89.1% in 2024, "reflecting a challenging medical cost trend environment in all our segments" [6]; the segment split showed Marketplace MCR moving from 75.4% to 90.6% [7] and Medicaid MCR moving from 90.3% to 91.8%, characterized as a "rate and trend imbalance" management believes is temporary [8].

Short-thesis ledger — allegation, evidence, company response, unresolved risk

No Results

Both topics the plaintiffs lean on were disclosed risk factors before the class period. The FY2024 10-K already characterized the Marketplace business as "volatile and unpredictable" [9], and the FY2025 10-K's risk-factor section explicitly walks through the financial sensitivity — a one-percentage-point move in the consolidated MCR (91.7% → 92.7%) would have reduced FY2025 diluted EPS from $8.92 to roughly $2.72, a $6.20 swing [10]. The Critical Audit Matter in the FY2025 audit report singles out IBNP claims reserves as a complex, judgmental estimate but does not identify a material weakness or restatement [11]. That combination — pre-existing risk-factor disclosure plus auditor judgment-but-no-defect — is the central defensive evidence the company would lean on; the live legal question is the timing of management's knowledge of the magnitude of the cost-trend deterioration during 1H 2025.

Management framing — what the call transcripts actually say

The qualitative case for and against a forward short on MOH rests heavily on whether management's "temporary, rate-cycle" framing of 2025 is credible. The Q3 FY2025 call carried management's most explicit rebuttal: CEO Joe Zubretsky characterized the operating environment as "inclement weather rather than climate change, metaphorically meaning temporary rather than permanent" and argued Medicaid is expected to "recalibrate to target margins" as rates catch up [12]. On the Q2 call he described 2025 as a year in which "we power through short-term industry-wide challenges and strive to deliver superior sector performance" [13]. On Q3, management quantified the EPS arithmetic: the original $24.50 guide was cut by $10.50 in total, with half of the cut from Marketplace and only one-third from Medicaid — a meaningful tell because Medicaid is 75% of revenue but only one-third of the miss, supporting the "rate-cycle catch-up" thesis [5].

This is the variant-perception axis a short would attack: if 2026 Medicaid rates do not close the gap, the "temporary" framing weakens and the live litigation becomes more damaging; if rates do catch up and Marketplace is meaningfully de-risked (the company has already narrowed Marketplace participation for 2026), the short thesis decays.

Borrow, locate, public net-short

No borrow-fee, utilization, lendable-supply, hard-to-borrow, locate-friction, or public net-short threshold-disclosure rows were staged for MOH in this run, and the latter regime does not apply to a US-listed name. There is no source-backed evidence here of borrow pressure or hard-to-borrow status; absence of evidence is the only honest conclusion.

Peer context

No peer short-interest rows were staged, so cross-name positioning relative to managed-care peers (UNH, ELV, CNC, HUM, CVS) cannot be assessed in this tab. Any peer-relative crowding claim would need to be sourced before being made.

Market setup — what the tape says, what it does not

The staged price series covers only March 18, 2026 → June 18, 2026 (66 trading days), opening at $184.50 and closing at $194.76 on the last bar — a calm, low-volume window that does not span either of the 2025 guidance cuts. The major tape event in the contested period is the $38.08 single-day drop on July 24, 2025 reported by plaintiff counsel after the Q2 guidance cut; that figure is sourced from third-party press releases rather than from a primary-record page, and the corpus does not contain a same-day intraday print to cite. Without intraday volume around the catalysts and without reported short-interest snapshots before and after each cut, the market-setup module collapses to a directional observation: the catalysts that the litigation hinges on are behind the company, the cost-trend and rate-cycle catalysts a short would lean on (2026 Medicaid rate updates, Marketplace pricing reset, OBBBA implementation) are still ahead [14].

Evidence limitations

No Results

Bottom line for sizing and risk

For positioning: no actionable read — reported short interest is missing, so this tab cannot tell a PM whether positioning is crowded, light, rising, or falling. Build the position thesis on the underlying fundamentals, not on assumed crowding.

For thesis risk: a real, documented short thesis exists, with a securities class action and a derivative suit pending, both anchored to disclosure timing around 2025 guidance cuts and the Marketplace MCR jump from 75.4% to 90.6% — not to fraud, accounting restatement, or going-concern doubt. The defensive disclosures (Marketplace volatility as a standing risk factor, IBNP as a CAM rather than a material weakness, a still-running buyback program with $500M of authorization remaining) are credible but do not resolve the litigation. Treat litigation outcome and 2026 Medicaid rate-vs-trend reset as the live binary catalysts, and re-run this analysis once reported short-interest data is available to confirm whether short positioning has actually built up around them.

References

Generated Jun 19, 2026 10:03 UTC